A novel idea in cancer research, that stem cells are at the source of all solid tumors, has generated a $1.4 billion deal for Redwood City biotech OncoMed Pharmaceuticals Inc. The company doesn’t have a product close to market, but GlaxoSmithKline nevertheless offered a deal that is said to be the biggest ever for a preclinical company.
